OBJECTIVE: To investigate the cost-effectiveness of a comprehensive programme for @entity6371 launched in four sites in China in 2011. METHODS: In 2011-2012, we reviewed the records of 172 @entity1 with @entity6371 who enrolled in the comprehensive programme and we collected relevant administrative data from hospitals and China's public health agency. For comparison, we examined a cohort of 81 @entity1 who were treated for @entity6371 in 2006-2009. We performed a cost-effectiveness analysis, from a societal perspective, that included probabilistic uncertainty. We measured early treatment outcomes based on three-month culture results and modelled longer-term outcomes to facilitate estimation of the comprehensive programme's cost per disability-adjusted life-year (DALY) averted. FINDINGS: The comprehensive programme cost 8837 United States dollars (US ) per @entity1 treated. Low enrolment rates meant that some fixed costs were higher, per @entity1 , than expected. Although the comprehensive programme appeared 30 times more costly than the previous one, it resulted in greater health benefits. The comprehensive programme, which cost US    639 (95% credible interval: 112 to 1322) per DALY averted, satisfied the World Health Organization's criterion for a very cost-effective intervention. CONCLUSION: The comprehensive programme, which included rapid screening, standardized care and financial protection, improved individual outcomes for @entity6371 in a cost-effective manner. To support post-2015 global heath targets, the comprehensive programme should be expanded to non-residents and other areas of China.

Cost-effectiveness of a comprehensive programme for XXXX in China.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity6371 :: ('MESH:D018088', 'Disease') :: ['drug-resistant tuberculosis', 'MDR tuberculosis']
@entity6371 :: (MESH:D018088,Disease) :: ['drug-resistant tuberculosis']
